Quest Diagnostics Reports Strong FY2025 Results, Boosts Dividend 7.5%, and Authorizes $1 Billion Share Buyback
DGX sits 34% above its 52-week low of $157.2.
Summary
Quest Diagnostics reported strong financial results for fiscal year 2025, driven by revenue growth and increased profitability, alongside a 7.5% dividend hike and a new $1 billion share repurchase authorization, signaling confidence and commitment to shareholder returns.
Key Events · Earnings and Guidance · DGX
-
Strong Fiscal Year 2025 Financial Performance
Net revenues increased by 11.8% to $11.035 billion, operating income rose by 15.6% to $1.556 billion, and diluted earnings per share grew by 13.8% to $8.75. Organic requisition volume was up 3.4%.
-
Increased Shareholder Returns
The Board of Directors authorized a 7.5% increase in the quarterly cash dividend from $0.80 to $0.86 per share, effective April 2026. Additionally, an extra $1 billion was authorized for share repurchases, building on the $452 million in repurchases during 2025.
-
Strategic Acquisitions and Investments
In 2025, the company acquired select assets of Spectra Laboratories for $84 million and entered a joint venture with Corewell Health. A multi-year 'Project Nova' was initiated in February 2025 to modernize IT processes with estimated expenditures of $250M-$310M through 2031-2032, with $60M planned for 2026. A collaboration with Google on AI was also announced.
-
Regulatory Clarity on LDTs
A U.S. District Court vacated the FDA's LDT (Laboratory Developed Test) rule in March 2025, clarifying that the FDA does not have authority to regulate LDTs, a significant development for the diagnostics industry.
Analysis · DGX · Industrial Applications And Services
Quest Diagnostics delivered robust financial performance for fiscal year 2025, with significant increases across key metrics including net revenues, operating income, and diluted EPS. The company's Diagnostic Information Services (DIS) segment was a primary driver of growth, benefiting from recent acquisitions. Management demonstrated a strong commitment to shareholder returns by increasing the quarterly cash dividend by 7.5% and authorizing an additional $1 billion for share repurchases. Strategic investments in IT modernization through 'Project Nova' and a collaboration with Google on AI are expected to enhance operational efficiency and customer experience in the long term. A notable regulatory development for the diagnostics industry was the U.S. District Court vacating the FDA's LDT rule, which could reduce regulatory burdens. While the 'One Big Beautiful Bill Act' presents a minor long-term revenue headwind, its impact is not expected to be material for 2026.
At the time of this filing, DGX was trading at $211.10 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $23.5B. The 52-week trading range was $157.20 to $213.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.